Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new antibody-drug conjugate, ixotatug vedotin, is turning heads in oncology. In the phase 1 CATALINA-1 trial, it achieved a 45.5% objective response rate in patients with heavily pretreated recurrent germ cell tumors — including those who had already failed stem cell transplants. One patient with testicular cancer has maintained a response for nearly four years.
A new antibody-drug conjugate (ADC) is showing real promise for patients with recurrent germ cell tumors (GCTs) who have run out of options. Ixotatug vedotin (TORL-1-23), which targets a protein called claudin 6 (CLDN6), produced meaningful responses as a monotherapy in the phase 1 CATALINA-1 trial — even in patients who had previously undergone high-dose chemotherapy with stem cell transplants, a notoriously difficult-to-treat group.
Results were presented at the 2026 ESMO Congress, with lead investigator Dr. Darren Feldman of Memorial Sloan Kettering describing it as "some of the best activity of any agent" he's studied in 20 years of researching refractory GCTs. A phase 2 trial is now being anticipated.
By the Numbers:
Why it matters: Recurrent GCTs after platinum-based chemotherapy and stem cell transplant represent a major unmet need in oncology. Ixotatug vedotin's early efficacy signals — especially the near-four-year response in one patient — suggest this CLDN6-targeted ADC could become a meaningful new option for a patient population with very few alternatives.
